<DOC>
	<DOCNO>NCT00254891</DOCNO>
	<brief_summary>To assess efficacy safety PF-3512676 administer combination paclitaxel/carboplatin chemotherapy first-line treatment patient locally advanced metastatic Non-Small-Cell Lung Cancer ( NSCLC ) compare efficacy safety paclitaxel</brief_summary>
	<brief_title>Trial Paclitaxel/Carboplatin + PF-3512676 v Paclitaxel/Carboplatin Alone Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PF-3512676 dosing stop 20 June 2007 response DSMC recommendation close trial , cite lack efficacy concern primary reason safety issue ( sepsis ) also contribute decision . Subjects allow complete standard care treatment/survival follow-up . Data collection complete 17 July 2008 .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Advanced NonSmallCell Lung Cancer ( NSCLC ) stage IIIB pleural effusion stage IV No prior systemic treatment NonSmallCell Lung Cancer ( NSCLC ) chemotherapy , immunotherapy , biologic response modifier investigational drug Eastern Cooperative Oncology Performance Status ( ECOG PS ) 0 1 Small cell carcinoid lung cancer Known Central Nervous System ( CNS ) metastasis Preexisting autoimmune antibody mediate disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>advanced carcinoma , non-small cell lung , Phase III , Paclitaxel , Taxol , Carboplatin , Paraplatin , PF-3512676 , immunotherapy , immune modulator</keyword>
</DOC>